Shanghai Frontiers Science Center for Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China State Key Laboratory of ...

A BLA has been filed for bentracimab and, if approved, has the potential to be the first therapy to reverse the effects of Brilinta for patients who have bleeding events or who need urgent surgery.

The REVERSE-IT trial showed 94.3% of patients achieved normal clotting, with 100% in surgery and 83.1% with major bleeding. Bentracimab's safety profile was favorable, with no serious allergic ...